계명대학교 의학도서관 Repository

Role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy

Metadata Downloads
Author(s)
Min Kyu KangDongryul OhKwan Ho ChoSung Ho MoonHong-Gyun WuDae-Seog HeoYong Chan AhnKeunchil ParkHyo Jung ParkJun Su ParkKi Chang KeumJihye ChaJun Won KimYeon-Sil KimJin Hyoung KangYoung-Taek OhJi-Yoon KimSung Hwan KimJin-Hee KimChang Geol Lee
Keimyung Author(s)
Kim, Jin Hee
Department
Dept. of Radiation Oncology (방사선종양학)
Journal Title
Cancer Research and Treatment
Issued Date
2015
Volume
47
Issue
4
Keyword
Nasopharyngeal carcinomaRadiotherapyChemotherapyChemoradiotherapy
Abstract
Purpose
To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal
carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy
with or without chemotherapy.
Materials and Methods
From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002
stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals
in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant
chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in
80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17.
Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy
to 74.2 Gy (median, 70 Gy).
Results
Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last followup,
13 patients had died and 32 had experienced treatment failure; locoregional failure
occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free
survival, distant metastasis-free survival, progression-free survival, and overall survival were
86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the
significant prognostic factors were concurrent chemotherapy and N stage for locoregional
relapse-free survival, concurrent chemotherapy for progression-free survival, and age and
N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved
distant metastasis-free survival.
Conclusion
Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival
and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant
chemotherapy failed to improve either.
Keimyung Author(s)(Kor)
김진희
Publisher
School of Medicine
Citation
Min Kyu Kang et al. (2015). Role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Research and Treatment, 47(4), 871–878. doi: 10.4143/crt.2014.141
Type
Article
ISSN
1598-2998
DOI
10.4143/crt.2014.141
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33043
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.